131 related articles for article (PubMed ID: 16215959)
21. The emergence of peptides as therapeutic drugs for the inhibition of HIV-1.
Huther A; Dietrich U
AIDS Rev; 2007; 9(4):208-17. PubMed ID: 18219364
[TBL] [Abstract][Full Text] [Related]
22. Partnership between academia and industry for drug discovery in Alzheimer's disease.
Ivinson AJ; Lane R; May PC; Hosford DA; Carrillo MC; Siemers ER
Alzheimers Dement; 2008 Mar; 4(2):80-8. PubMed ID: 18631952
[TBL] [Abstract][Full Text] [Related]
23. Biomarkers: a valuable tool in clinical research and medical practice.
Carini C
IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
[TBL] [Abstract][Full Text] [Related]
24. From laboratory to Phase I/II cancer trials with recombinant biotherapeutics.
Tolner B; Smith L; Hillyer T; Bhatia J; Beckett P; Robson L; Sharma SK; Griffin N; Vervecken W; Contreras R; Pedley RB; Begent RH; Chester KA
Eur J Cancer; 2007 Nov; 43(17):2515-22. PubMed ID: 17933516
[TBL] [Abstract][Full Text] [Related]
25. Translational research in the pharmaceutical industry: from theory to reality.
Sultana SR; Roblin D; O'Connell D
Drug Discov Today; 2007 May; 12(9-10):419-25. PubMed ID: 17467579
[TBL] [Abstract][Full Text] [Related]
26. [Is the pharmaceutical industry really as bad as its reputation?].
Prat EH
Wien Med Wochenschr; 2005 Nov; 155(21-22):502-12. PubMed ID: 16425111
[TBL] [Abstract][Full Text] [Related]
27. Assessment by human research ethics committees of potential conflicts of interest arising from pharmaceutical sponsorship of clinical research.
Newcombe JP; Kerridge IH
Intern Med J; 2007 Jan; 37(1):12-7. PubMed ID: 17199839
[TBL] [Abstract][Full Text] [Related]
28. Developing a tool for the preparation of GMP audit of pharmaceutical contract manufacturer.
Linna A; Korhonen M; Mannermaa JP; Airaksinen M; Juppo AM
Eur J Pharm Biopharm; 2008 Jun; 69(2):786-92. PubMed ID: 18191391
[TBL] [Abstract][Full Text] [Related]
29. Relationship between drug company funding and outcomes of clinical psychiatric research.
Kelly RE; Cohen LJ; Semple RJ; Bialer P; Lau A; Bodenheimer A; Neustadter E; Barenboim A; Galynker II
Psychol Med; 2006 Nov; 36(11):1647-56. PubMed ID: 16893480
[TBL] [Abstract][Full Text] [Related]
30. Continuous processes for the production of pharmaceutical intermediates and active pharmaceutical ingredients.
LaPorte TL; Wang C
Curr Opin Drug Discov Devel; 2007 Nov; 10(6):738-45. PubMed ID: 17987525
[TBL] [Abstract][Full Text] [Related]
31. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
32. [Strategy of molecular drug design: hits, leads and drug candidates].
Guo ZR
Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
[TBL] [Abstract][Full Text] [Related]
33. [Pharmaceutical technology: development and research].
Traisnel M
Bull Acad Natl Med; 1994 Jun; 178(6):1169-74; discussion 1174-6. PubMed ID: 7994587
[TBL] [Abstract][Full Text] [Related]
34. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
Blagden N; de Matas M; Gavan PT; York P
Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic peptides: technological advances driving peptides into development.
Sato AK; Viswanathan M; Kent RB; Wood CR
Curr Opin Biotechnol; 2006 Dec; 17(6):638-42. PubMed ID: 17049837
[TBL] [Abstract][Full Text] [Related]
36. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
Federsel HJ
Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
[TBL] [Abstract][Full Text] [Related]
37. [Organisation of clinical research in France: the new missions of inter-regional delegations for clinical research].
Jaillon P
Bull Acad Natl Med; 2008 May; 192(5):929-37; discussion 937-9. PubMed ID: 19238783
[TBL] [Abstract][Full Text] [Related]
38. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organization
World Health Organ Tech Rep Ser; 2005; 929():1-142, backcover. PubMed ID: 16353684
[TBL] [Abstract][Full Text] [Related]
39. Design and synthesis of novel antimicrobial peptides on the basis of alpha helical domain of Tenecin 1, an insect defensin protein, and structure-activity relationship study.
Ahn HS; Cho W; Kang SH; Ko SS; Park MS; Cho H; Lee KH
Peptides; 2006 Apr; 27(4):640-8. PubMed ID: 16226345
[TBL] [Abstract][Full Text] [Related]
40. Bioactive peptides: signaling the future.
Fields K; Falla TJ; Rodan K; Bush L
J Cosmet Dermatol; 2009 Mar; 8(1):8-13. PubMed ID: 19250159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
